The estimated Net Worth of Scott Terrillion is at least $1.98 Milhão dollars as of 5 April 2024. Mr. Terrillion owns over 2,753 units of Cara Therapeutics Inc stock worth over $25,592 and over the last 7 years he sold CARA stock worth over $565,947. In addition, he makes $1,385,430 as Chief Compliance Officer, General Counsel, e Secretary at Cara Therapeutics Inc.
Scott has made over 18 trades of the Cara Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,753 units of CARA stock worth $2,285 on 5 April 2024.
The largest trade he's ever made was selling 7,770 units of Cara Therapeutics Inc stock on 8 February 2024 worth over $4,118. On average, Scott trades about 1,996 units every 69 days since 2018. As of 5 April 2024 he still owns at least 88,247 units of Cara Therapeutics Inc stock.
You can see the complete history of Mr. Terrillion stock trades at the bottom of the page.
Scott M. Terrillion serves as Chief Compliance Officer, General Counsel, Secretary of the Company. Mr. Terrillion brings over 20 years of diverse pharmaceutical industry experience from varying legal and business roles in the public, private and not-for-profit sectors. Mr. Terrillion spent 15 years at Boehringer Ingelheim Pharmaceuticals, Inc., a research-driven pharmaceutical company, where he served as Vice President, Associate General Counsel. At Boehringer, Mr. Terrillion built and led the legal team supporting the global company’s U.S. human pharmaceutical business during a period of rapid, industry-leading growth. Mr. Terrillion also spent two years at Mesoblast, Inc., a publicly traded emerging biotech, as the company’s Vice President, Associate General Counsel and Head of Compliance. Mr. Terrillion began his legal career at Nixon, Hargrave, Devans & Doyle (now Nixon Peabody LLP), a large general practice law firm, where he was an associate in the Health Care and Technology/Intellectual Property Practice groups. A licensed pharmacist, Mr. Terrillion began his professional career as a community pharmacist and later served as Director of Pharmacy for Preferred Care, Inc., an HMO insurance provider. Mr. Terrillion received his B.S. in Pharmacy from the Albany College of Pharmacy and Health Sciences, where he serves on the Board of Trustees, and a Juris Doctor, magna cum laude, from Albany Law School. He is a member of the New York bar and authorized house counsel in Connecticut..
As the Chief Compliance Officer, General Counsel, e Secretary of Cara Therapeutics Inc, the total compensation of Scott Terrillion at Cara Therapeutics Inc is $1,385,430. There are 3 executives at Cara Therapeutics Inc getting paid more, with Joana Goncalves having the highest compensation of $3,736,190.
Scott Terrillion is 57, he's been the Chief Compliance Officer, General Counsel, e Secretary of Cara Therapeutics Inc since 2016. There are 5 older and 12 younger executives at Cara Therapeutics Inc. The oldest executive at Cara Therapeutics Inc is Harrison Bains, 76, who is the Independent Director.
Scott's mailing address filed with the SEC is C/O CARA THERAPEUTICS, INC., 400 ATLANTIC STREET, SUITE 500, STAMFORD, CT, 06901.
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum, eVentures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Cara Therapeutics Inc executives and other stock owners filed with the SEC include: